It's Wednesday, July 28th, welcome to Marketfooler, I'm Chris Hill with me today, Sarah Gentry

and Connor Allen.

Thanks for being here.

Thank you, Chris.

Thank you, Connor.

We got a bunch of things to get to, including Netflix.

We're going to start today with Johnson and Johnson.

Second quarter profits and revenue for J&J came in higher than expected.

They also raised guidance for the full fiscal year.

Let me tell you, Sarah, was this quarter as good as it looks on the surface?

Because on the surface, you combined the results with the guidance raised.

This looks pretty damn good.

Yeah.

I mean, on the surface, they had a phenomenal quarter in terms of growth rates as they really

do return to pre-pandemic levels and consumers return back to normal life and spending habits.

The key is here, though, and I think really with those really large growth rates you see

is that you're comparing it to year-over-year growth, so back in 2020, they experienced a huge

a kind of revenue.

A lot of those growth rates look pretty inflated, so you had revenue increasing by over 27%

and earnings for share growing about 73% year-over-year, but it's just really key that we take that

with a bit of a grain of salt.

But something I do want to know is that J&J's medical device segment experienced a ton

...